We have located links that may give you full text access.
Clinical and radiological septic joint analysis of spontaneous sternoclavicular joint infections: Achieving the best Outcomes- A systems engineering approach.
European Journal of Cardio-thoracic Surgery 2024 March 29
PURPOSE: Spontaneous sternoclavicular joint infection (SSCJI) is a rare and poorly understood disease process. This study aims to identify factors guiding effective management strategies for SSCJI by using data mining.
METHODS: An IRB-approved retrospective review of patients from two large hospitals (2010 to 2022) was conducted. Spontaneous sternoclavicular joint infection is defined as a joint infection without direct trauma or radiation, direct instrumentation, or contiguous spread. An interdisciplinary team consisting of thoracic surgeons, radiologists, infectious disease specialists, orthopedic surgeons, hospital information experts, and systems engineers selected relevant variables. Small set data mining algorithms, utilizing systems engineering, were employed to assess the impact of variables on patient outcomes.
RESULTS: A total of 73 variables were chosen and 54 analyzed against 11 different outcomes. Forty-seven patients (mean age, 51 (22-82); 77% male) met criteria. Among them, 34 underwent early joint surgical resection (<14 days), 5 patients received delayed surgical intervention (>14 days), and 8 had antibiotic-only management. The antibiotic-only group had comparable outcomes. Indicators of poor outcomes were soft tissue fluid >4.5 cm, previous SSCJI, moderate/significant bony fragments, HgbA1c >13.9%, and moderate/significant bony sclerosis.
CONCLUSIONS: This study suggests that targeted antibiotic-only therapy should be considered initially for spontaneous sternoclavicular joint infection cases while concurrently managing comorbidities. Patients displaying indicators of poor outcomes or no symptomatic improvement after antibiotic-only therapy should be considered for surgical joint resection (central image).
METHODS: An IRB-approved retrospective review of patients from two large hospitals (2010 to 2022) was conducted. Spontaneous sternoclavicular joint infection is defined as a joint infection without direct trauma or radiation, direct instrumentation, or contiguous spread. An interdisciplinary team consisting of thoracic surgeons, radiologists, infectious disease specialists, orthopedic surgeons, hospital information experts, and systems engineers selected relevant variables. Small set data mining algorithms, utilizing systems engineering, were employed to assess the impact of variables on patient outcomes.
RESULTS: A total of 73 variables were chosen and 54 analyzed against 11 different outcomes. Forty-seven patients (mean age, 51 (22-82); 77% male) met criteria. Among them, 34 underwent early joint surgical resection (<14 days), 5 patients received delayed surgical intervention (>14 days), and 8 had antibiotic-only management. The antibiotic-only group had comparable outcomes. Indicators of poor outcomes were soft tissue fluid >4.5 cm, previous SSCJI, moderate/significant bony fragments, HgbA1c >13.9%, and moderate/significant bony sclerosis.
CONCLUSIONS: This study suggests that targeted antibiotic-only therapy should be considered initially for spontaneous sternoclavicular joint infection cases while concurrently managing comorbidities. Patients displaying indicators of poor outcomes or no symptomatic improvement after antibiotic-only therapy should be considered for surgical joint resection (central image).
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app